Mylan inflammation news

Mylan will pay $465 million to the U.S. Department of Justice and other government entities to “resolve questions” about the classification of Mylan’s EpiPen epinephrine auto-injector in the Medicaid Drug Rebate Program. The company said the settlement terms “do not provide for any finding of wrongdoing.” ...